CONMED Corporation reports news on its medical technology business, which provides surgical devices and equipment used by surgeons and other healthcare professionals across multiple specialties. Company updates commonly cover sales trends, domestic and international revenue, GAAP and adjusted earnings, full-year outlooks, and management presentations in the healthcare sector.
Recurring announcements also address portfolio optimization, including the exit or reduction of certain gastroenterology products, and the company’s focus on minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair. Other corporate news includes finance leadership changes and operating initiatives tied to supply chain execution, product rationalization, and margin profile.
CONMED Corporation (NYSE: CNMD) announced that Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 2:40 p.m. ET. A live webcast will be accessible via the company’s website. CONMED specializes in surgical devices for minimally invasive procedures across various medical specialties, including orthopedics and gastroenterology.
CONMED Corporation (NYSE: CNMD) has announced that Curt R. Hartman, Chair of the Board, President, and CEO, along with Todd W. Garner, Executive VP and CFO, will present at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 2:40 ET. Interested parties can access a live webcast through the Company’s website. CONMED specializes in providing innovative surgical devices for minimally invasive procedures across various medical specialties, including orthopedics and general surgery.
CONMED Corporation (NYSE: CNMD) reported a 4.6% year-over-year increase in sales for Q3 2021, totaling $248.8 million. Domestic sales rose 1.6%, while international sales grew by 8.5%. Diluted EPS was $0.47, up from $0.23 in Q3 2020. Adjusted diluted EPS decreased to $0.80 from $0.88. The company adjusted its full-year revenue guidance to $1.015 billion - $1.025 billion due to ongoing pandemic impacts. Full-year adjusted diluted EPS guidance is now $3.18-$3.23, slightly revised from $3.15-$3.25.
CONMED Corporation (NYSE: CNMD) will release its financial results for the third quarter of 2021 on October 27, 2021, after the market closes. A conference call to discuss these results is scheduled for 4:30 p.m. ET on the same day. Participants can join via phone or through a webcast available on CONMED's website. The call will be re-playable from 7:30 p.m. ET on the same day until 7:30 p.m. ET on November 3, 2021.
CONMED Corporation (NYSE: CNMD) announced that Curt R. Hartman, Chair and CEO, along with CFO Todd W. Garner, will participate in a virtual fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference on September 14, 2021, at 5:00 p.m. ET.
The session will be available for live viewing on the Company’s website, www.conmed.com, and can be replayed later.
CONMED specializes in surgical devices for minimally invasive procedures across various medical fields.
CONMED Corporation (NYSE: CNMD) has declared a quarterly cash dividend of $0.20 per share, payable on October 5, 2021, to shareholders of record as of September 15, 2021. This decision reflects the company’s commitment to returning value to shareholders amidst ongoing challenges, including those presented by the COVID-19 pandemic. CONMED specializes in medical technology, offering surgical devices for minimally invasive procedures across various medical fields.
CONMED Corporation (NYSE: CNMD) reported a strong financial performance for Q2 2021, with sales reaching $255.2 million, a 61.7% increase year over year. Domestic revenue surged 64.2%, while international sales climbed 58.6%. Diluted EPS was $0.41, up from a loss of $0.96 in Q2 2020. The company raised its full-year revenue guidance to between $1.015 billion and $1.035 billion and adjusted EPS guidance to $3.15 to $3.25, reflecting confidence in ongoing operational improvements and market recovery.
CONMED Corporation (NYSE: CNMD) is set to report its Q2 2021 financial results on July 28, 2021, after market close. A conference call will be held at 4:30 p.m. ET to discuss the results. Interested parties can join the call by dialing 1-844-889-7792 (domestic) or +1-661-378-9936 (international) with passcode 7138188. The call will also be available via webcast on the CONMED website, and a recording will be accessible from 7:30 p.m. ET on the same day until August 4, 2021.
CONMED Corporation (NYSE: CNMD) declared a quarterly cash dividend of $0.20 per share. This dividend is payable on July 6, 2021, to shareholders of record as of June 15, 2021. CONMED specializes in medical technology, offering surgical devices for minimally invasive procedures across various specialties, including orthopedics and general surgery. For additional details, visit www.conmed.com.
CONMED Corporation (NYSE: CNMD) reported first-quarter 2021 financial results, highlighting a sales increase of 8.7% year-over-year to $232.7 million. Domestic revenue rose 4.3%, while international revenue surged 14.3%. Diluted EPS rose 55.0% to $0.31. The company enhanced its 2021 revenue guidance to between $1.0 billion and $1.03 billion, up from $975 million to $1.02 billion. Adjusted diluted EPS guidance is now $3.05 to $3.20, improved from $2.85 to $3.05.